Bambusa

Bambusa Therapeutics is a biotechnology company focused on the discovery and development of novel bispecific antibodies for the treatment of various cancers. The company's technology platform, originated from the University of Texas at Austin, enables the design of antibodies that can simultaneously bind to tumor cells and activate immune effector cells. By optimizing the geometry and affinity of these molecules, Bambusa aims to overcome limitations of first-generation bispecific therapies. In March 2021, the company was acquired by Takeda Pharmaceutical Company to integrate its innovative antibody engineering assets into Takeda's oncology portfolio.